In this week’s episode of Dividend Talk we kick off with Kimberly-Clark’s surprise move to buy Kenvue, asking if it’s a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.

Novo Nordisk’s obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer’s high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on’s double-digit dividend hike and Simon Property Group’s steady income growth for REIT investors.

Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.

In the listener Q&A, we cover:

• Dividend tax strategies and EU exit taxes

• How to handle rising wealth taxes as a dividend investor

• Fair-value analysis vs Morningstar valuations

• Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition

• Thoughts on Unilever’s upcoming Magnum spinoff

SEE YOU ON THE INSIDE!!

Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.L

Join us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠

[Twitter] – @DividendTalk_ , @European_DG

[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠

[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠

[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj